The following is a summary of “Screening for primary aldosteronism in 1,181 Swedish primary care patients with hypertension,” ...

Vienna-based aTENSION.life, a high-tech life science startup, announced its launch to transform hypertension treatment, utilising its proprietary ALDO+ ...

The aldosterone-renin ratio (ARR) has gained popularity as a screening test for primary hyperaldosteronism, a probably underdiagnosed cause of hypertension. However, studies have yielded varying ...

Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (C.-H.T., J.M ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Baseline characteristics were well balanced among the three groups with the exception of lower use of renin-angiotensin-aldosterone system ... failure used for our primary outcome.

Radnor, Pennsylvania-based Mineralys is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other ...

Aldosterone is known to bind to these receptors ... spironolactone, triamterene). The primary risk of eplerenone is hyperkalemia (which can cause serious arrhythmias). Periodic monitoring of ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit ... Baxdrostat is a highly selective aldosterone synthase inhibitor; phase 1 studies showed ...

The primary outcome was change in 24-hour average SBP from baseline ... The use of a therapy which targets aldosterone production is promising as a new treatment in resistant hypertension if these ...